Table 2 Procedures and therapies

Noninvasive ventilation, n (%);

days, median (IQR)

14 (45.2);

2 (1–3)

8 (34.8);

2 (1–3)

6 (75.0);

2 (1–4)

0.097

Invasive ventilation, n (%);

days, median (IQR)

27 (87.1);

8 (4–17)

22 (95.7);

8 (2–17)

5 (62.5);

11 (5–17)

0.043

High-frequency oscillation

11 (35.5)

11 (47.8)

0 (0.0)

0.028

Prone positioning, n (%);

days, median (IQR)

5 (16.1);

4 (2–5)

5 (21.7);

4 (2–5)

0 (0.0);

0 (0.0)

1.00

ECMO, n (%);

days, median (IQR)

1 (3.2);

13 (13–13)

1 (4.3);

13 (13–13)

0 (0.0);

0 (0.0)

1.00

Vasopressors^b, n (%);

days, median (IQR)

25 (80.6);

4 (2–9)

22 (95.7);

5 (2–9)

3 (37.5);

3 (2–3)

0.002

Intermittent hemodialysis, n (%);

days, median (IQR)

3 (9.7);

5 (2–5)

2 (8.7);

4 (2–4)

1 (12.5);

7 (7–7)

1.00

Continuous RRT, n (%);

days, median (IQR)

16 (51.6);

6 (2–11)

14 (60.9);

7 (3–11)

2 (25.0);

2 (1–2)

0.113

 Oseltamivir

20 (64.5)

15 (65.2)

5 (62.5)

0.484

 Ribavirin/interferon alfa-2a

13 (41.9)

9 (39.1)

4 (50.0)

0.507

 Neuromuscular blockers

12 (38.7)

10 (43.5)

2 (25.0)

0.465

 Steroids^c

8 (25.8)

6 (26.1)

2 (25.0)

0.954